BIOPHYTIS (EPA:ALBPS) - Biophytis to attend BIO-Europe® in Hamburg
Transparency directive : regulatory news
Click here to download pdf version
Biophytis to attend BIO-Europe(r) in Hamburg
Paris (France), Cambridge (Massachusetts, United States), November 7, 2019,
08:00 CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company with a primary focus on the treatment of neuromuscular
diseases, announced today that the company is scheduled to attend BIO-Europe(r)
which will be held in Hamburg, Germany, November 11th to 13th 2019.
The management will host and participate in one-on-one meetings throughout the
conference where it will present the Company and developments of its lead drug
candidate Sarconeos (BIO101).
Biophytis is a clinical-stage biotechnology company focused on developing
therapeutics that slow the degenerative processes associated with aging and
improve functional outcomes for patients suffering from age-related diseases,
with a primary focus on neuromuscular diseases.
Biophytis' lead drug candidate, Sarconeos (BIO101), is an orally administered
small molecule, which is currently in a Phase 2b clinical trial for sarcopenia
(SARA-INT) in the U.S. and Europe. A pediatric formulation of Sarconeos
(BIO101) is being developed for the treatment of Duchenne muscular dystrophy
(DMD). Biophytis expects Sarconeos (BIO101) to be ready to enter the clinic for
DMD in 2020, subject to regulatory approval. Biophytis' preclinical drug
candidate, Macuneos (BIO201), is an orally administered small molecule in
development for the treatment of retinopathies, including dry agerelated
macular degeneration (AMD) and Stargardt disease.
Biophytis is headquartered in Paris, France, and has offices in Cambridge,
Massachusetts. The Company's ordinary shares are listed on Euronext Growth
Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on Biophytis' website (www.biophytis.com).
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to securities
of Biophytis in any country. Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements and estimates,
which speak only as of the date hereof. Other than as required by applicable
law, Biophytis undertakes no obligation to update or revise the information
contained in this press release. This press release has been prepared in both
French and English. In the event of any differences between the two texts, the
French language version shall prevail.
Biophytis Investor Relations Contact
Daniel Schneiderman, CFO
Tel: +1 (857) 220-9720
Citigate Dewe Rogerson
Sylvie Berrebi / David Dible / Nathaniel Dahan / Quentin Dussart
Tel: +33 (0)1 55 30 70 91 / +44 (0)20 76389571